

UNAUDITED FINANCIAL RESULTS

(₹ Lacs)

Particulars	Quarter Ended			Nine Months Ended		Year Ended
	31.12.2014 (Unaudited)	30.09.2014 (Unaudited)	31.12.2013 (Unaudited)	31.12.2014 (Unaudited)	31.12.2013 (Unaudited)	31.03.2014 (Audited)
PART I						
1 Income from operations						
a) Net Sales/income from operations (Net of excise duty)	1,504.84	1,891.29	1,423.51	5,088.94	5,179.87	6,831.56
b) Other Operating Income	8.34	2.37	1.01	11.99	4.27	5.76
Total Income from operations (net)	1,513.18	1,893.66	1,424.52	5,100.93	5,184.14	6,837.32
2 Expenses						
a) Cost of materials consumed	417.96	444.29	417.73	1,519.21	1,464.17	2,036.20
b) Purchases of stock-in-trade	419.50	394.10	571.82	1,570.42	1,700.14	2,286.52
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	146.42	325.54	(26.55)	105.37	125.88	72.87
d) Employee benefit expense	167.85	184.18	162.34	509.86	546.04	724.15
e) Depreciation / Amortisation Expense	39.81	39.05	24.26	116.21	72.99	97.35
f) Other expenses	308.01	379.08	308.74	1,053.06	1,109.37	1,513.32
Total Expenses	1,499.55	1,766.24	1,458.34	4,874.13	5,018.59	6,730.41
3 Profit / (Loss) from operations before Other Income, Finance Costs & exceptional items (1-2)	13.63	127.42	(33.82)	226.80	165.55	106.91
4 Other Income	10.76	14.91	14.98	33.61	36.13	54.72
5 Profit / (Loss) from ordinary activities before Finance Cost & exceptional items (3+4)	24.39	142.33	(18.84)	260.41	201.68	161.63
6 Finance costs	9.48	13.03	6.77	31.53	34.49	42.88
7 Profit / (Loss) from ordinary activities after finance cost but before exceptional items(5-6)	14.91	129.30	(25.61)	228.88	167.19	118.75
8 Exceptional item: Reversal of provision for diminution in value of investments	(71.60)	-	-	(71.60)	-	-
9 Profit / (Loss) from ordinary activities before tax (7-8)	86.51	129.30	(25.61)	300.48	167.19	118.75
10 Tax Expense	20.03	46.31	(8.10)	95.13	61.42	59.19
11 Net Profit / (Loss) from ordinary activities after tax (9-10)	66.48	82.99	(17.51)	205.35	105.77	59.56
12 Extraordinary items (net of tax expense)	-	-	-	-	-	-
13 Net Profit / (Loss) for the period (11-12)	66.48	82.99	(17.51)	205.35	105.77	59.56
14 Paid-up equity share capital (Face value of ₹ 10/- each)	491.70	491.70	491.70	491.70	491.70	491.70
15 Reserves excluding revaluation reserve	-	-	-	-	-	1,798.61
16 Earnings per share (₹)						
Basic & Diluted	1.35	1.69	(0.36)	4.18	2.15	1.21

PART II

A PARTICULARS OF SHAREHOLDING						
1 Public shareholding						
- Number of shares	2047033	2047033	2047033	2047033	2047033	2047033
- Percentage of shareholding	41.63%	41.63%	41.63%	41.63%	41.63%	41.63%
2 Promoters and Promoter group shareholding						
a) Pledged / Encumbered						
- Number of Shares	Nil	Nil	Nil	Nil	Nil	Nil
- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-	-	-
- Percentage of Shares (as a % of the total share capital of the Company)	-	-	-	-	-	-
b) Non - encumbered						
- Number of Shares	2869947	2869947	2869947	2869947	2869947	2869947
- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
- Percentage of Shares (as a % of the total share capital of the Company)	58.37%	58.37%	58.37%	58.37%	58.37%	58.37%
B NUMBER OF INVESTOR COMPLAINTS						
Pending at the beginning of the quarter	Nil					
Received during the quarter	3					
Disposed of during the quarter	3					
Remaining unresolved at the end of the quarter	Nil					

- Notes:**
- The above unaudited financial results as reviewed by the Audit Committee were approved and taken on record by the Board of Directors in their meeting held on January 30, 2015
 - The Auditors of the Company have carried out the limited review of the above unaudited financial results in terms of clause 41 of the Listing Agreement.
 - The entire operations of the Company relate to only one segment viz. 'Pharmaceuticals'.
 - Previous year's figures have been regrouped, wherever necessary.
 - In accordance with the provisions of Schedule II to the Companies Act, 2013, effective from 1st April, 2014, the Company has revised the useful lives of its fixed assets. As a consequence of such revision the charge for depreciation for the period is higher than the previously applied rates by ₹48.17 Lacs. For assets that have completed the useful lives as a consequence of the aforesaid revision, the carrying value as on 1st April, 2014 of ₹4.63 Lacs has been charged to the opening balance of the surplus in Statement of Profit & Loss net of deferred tax effect thereon of ₹ 2.38 Lacs.

By Order of the Board
For Makers Laboratories Limited
Purnima Jain
Whole Time Director

Place : Mumbai
Date : January 30, 2015

For MAKERS LABORATORIES LTD.

 PURNIMA JAIN
WHOLETIME DIRECTOR